Affimed

AFMD

Heidelberg, Germany· Est. 2000

affimed.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

AFMD · Stock Price

USD 0.18+0.00 (+0.00%)

Historical price data

Pipeline: 9 drugsFounded: 2000Employees: 100-250HQ: Heidelberg, Germany

Sector Ranking#80 in Immunotherapy / Immuno-Oncology #203 in Biologics / Biosimilars

Overview

Affimed is a Germany-based immuno-oncology company dedicated to developing first-in-class innate cell engagers (ICE®) for cancer. Its core achievement is the proprietary ROCK® platform, which generates tetravalent, bispecific antibodies engineered to potently activate NK cells and macrophages against tumors. The company's strategy centers on advancing its lead candidate, AFM13, in combination with allogeneic NK cells for relapsed/refractory Hodgkin lymphoma, while leveraging its platform to build a broader pipeline. Affimed operates as a public company, collaborating with key partners to validate and expand the potential of its innate immunity approach.

OncologyHematological Malignancies

Technology Platform

The ROCK® platform generates tetravalent, bispecific innate cell engagers (ICE®) in a unique 2:2 format, designed to potently activate natural killer cells and macrophages against cancer cells with high avidity and a favorable safety profile.

Pipeline

9 drugs in pipeline

Drug	Indication	Stage
AFM13	Hodgkin Lymphoma	Phase 2
AFM13	Peripheral T Cell Lymphoma	Phase 2
AFM24 + SNK01	Squamous Cell Carcinoma of Head and Neck	Phase 1/2
AFM24 + Atezolizumab 840 MG in 14 ML Injection	Advanced Solid Tumor	Phase 1/2
14 mg AFM24 + 40 mg AFM24 + 80 mg AFM24 + 160 mg AFM24 + 320...	Advanced Solid Tumor	Phase 1/2

Opportunities

Positive data from the pivotal AFM13-NK cell program in Hodgkin lymphoma could validate the entire ICE® platform, unlock significant value, and attract partnership or acquisition interest.

The approach also has broad potential application across other hematologic and solid tumors, representing a multi-billion dollar market opportunity.

Risk Factors

The company faces binary clinical risk with its lead asset, a constrained financial runway requiring dilutive or restrictive financing, and intense competition from both approved and investigational therapies in lymphoma and AML.

Operational complexity in manufacturing the combination therapy adds further execution risk.

Competitive Landscape

Affimed competes in the bispecific antibody space but is differentiated by its exclusive focus on innate immune effectors (NK cells/macrophages) versus mainstream T-cell engagers. In NK cell engagers, it faces emerging competition from companies like Innate Pharma/Sanofi and Dragonfly Therapeutics. Its lead program competes with later-line ADC, checkpoint inhibitor, and CAR-T therapies in Hodgkin lymphoma.